ArticleFrontiers in neurology2024

A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic lateral sclerosis.

Jason R Thonhoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.